This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Analysts Estimate Afya (AFYA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Afya (AFYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LINC vs. AFYA: Which Stock Is the Better Value Option?
by Zacks Equity Research
LINC vs. AFYA: Which Stock Is the Better Value Option?
LINC vs. AFYA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LINC vs. AFYA: Which Stock Is the Better Value Option?
New Strong Sell Stocks for September 28th
by Zacks Equity Research
YUM, VC, NKE, AFYA, and FLWS have been added to the Zacks Rank #5 (Strong Sell) List on September 28, 2021.
LRN vs. AFYA: Which Stock Is the Better Value Option?
by Zacks Equity Research
LRN vs. AFYA: Which Stock Is the Better Value Option?
LRN or AFYA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LRN vs. AFYA: Which Stock Is the Better Value Option?
Afya (AFYA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Afya (AFYA) delivered earnings and revenue surprises of -85.00% and -4.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Afya (AFYA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Afya (AFYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LRN vs. AFYA: Which Stock Is the Better Value Option?
by Zacks Equity Research
LRN vs. AFYA: Which Stock Is the Better Value Option?
LINC vs. AFYA: Which Stock Is the Better Value Option?
by Zacks Equity Research
LINC vs. AFYA: Which Stock Is the Better Value Option?
LRN or AFYA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LRN vs. AFYA: Which Stock Is the Better Value Option?
Strategic Education's (STRA) Capella Boosts FlexPath Portfolio
by Zacks Equity Research
Strategic Education (STRA) is set to include a balanced education format in its FlexPath portfolio at Capella University.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021
New Strong Sell Stocks for May 18th
by Zacks Equity Research
AFYA, BLU, CHRA, DHX, and EBMT have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2021
American Public (APEI)-Rio Salado Tie Up Over Online Education
by Zacks Equity Research
American Public Education (APEI) collaborates with Rio Salado to promote online education degree with seamless admission and make distance education affordable and accessible.
New Strong Buy Stocks for January 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
American Public's (APEI) Hondros to Open a Campus in Akron
by Zacks Equity Research
American Public (APEI) to combat nursing scarcity through new Hondros College campus in Akron, OH.
What Makes Afya Limited (AFYA) a New Strong Buy Stock
by Zacks Equity Research
Afya Limited (AFYA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adtalem (ATGE) Up 13% in 6 Months: More Room for Growth?
by Zacks Equity Research
Adtalem Global Education (ATGE) is riding high on various cost-saving initiatives, collaborations and focus on online learning.
All You Need to Know About Afya (AFYA) Rating Upgrade to Buy
by Zacks Equity Research
Afya (AFYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Afya (AFYA) Q3 Earnings Match Estimates
by Zacks Equity Research
Afya (AFYA) delivered earnings and revenue surprises of 0.00% and 3.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Afya (AFYA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Afya (AFYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Afya (AFYA) a New Buy Stock
by Zacks Equity Research
Afya (AFYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Timing the Market, Is it Possible? - October 07, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Timing the Market, Is it Possible? - September 18, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?